Novo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market

Read full story on MarketWatch
Share
Novo Nordisk’s lawsuit against Eli Lilly over ads highlights intense competition in GLP-1 market
AI disclosure

Summary

The Danish company Novo Nordisk says U.S.-based Lilly isn’t including the most up-to-date clinical information about its drugs.

Original reporting

Open original source

Related coverage

Read full article on MarketWatch

Get the AFBytes Brief

Major stories, AI-assisted analysis, and what to watch next. Free, monthly, unsubscribe anytime.